KLK3 and prostate cancer: From pre-clinical data on prostate cancer, PPARγ agonists may be acting, in part, by inhibiting transactivation of androgen-responsive genes [101]: Peroxisome proliferator-activated receptor γ agonists may down-regulate prostate-specific antigen expression in human prostate cancer [102].